{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=PLACEBO&page=71", "query": { "intervention": "PLACEBO", "page": 71 }, "page_size": 10 }, "pagination": { "page": 71, "page_size": 10, "total_count": 33121, "total_pages": 3313, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=PLACEBO&page=72&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=PLACEBO&page=70&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-01T19:20:19.346Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04482686", "title": "Trial of Combination Therapy to Treat COVID-19 Infection", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "COVID", "Covid-19", "Corona Virus Infection", "Coronavirus Infection", "Coronavirus-19", "SARS-CoV2", "SARS-CoV Infection" ], "interventions": [ { "name": "Ivermectin", "type": "DRUG" }, { "name": "Doxycycline Hcl", "type": "DRUG" }, { "name": "Zinc", "type": "DIETARY_SUPPLEMENT" }, { "name": "Vitamin D3", "type": "DIETARY_SUPPLEMENT" }, { "name": "Vitamin C", "type": "DIETARY_SUPPLEMENT" } ], "intervention_types": [ "DRUG", "DIETARY_SUPPLEMENT" ], "sponsor": "ProgenaBiome", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 31, "start_date": "2020-12-09", "completion_date": "2022-07-15", "has_results": false, "last_update_posted_date": "2024-09-24", "last_synced_at": "2026-11-01T19:20:19.346Z", "location_count": 1, "location_summary": "Ventura, California", "locations": [ { "city": "Ventura", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04482686" }, { "nct_id": "NCT00259870", "title": "SB-773812 Administered In Adults With Schizophrenia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Schizophrenia" ], "interventions": [ { "name": "SB-773812", "type": "DRUG" }, { "name": "Olanzapine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 338, "start_date": "2005-09", "completion_date": "2007-08", "has_results": false, "last_update_posted_date": "2017-03-23", "last_synced_at": "2026-11-01T19:20:19.346Z", "location_count": 18, "location_summary": "Birmingham, Alabama • Cerritos, California • Garden Grove, California + 15 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Cerritos", "state": "California" }, { "city": "Garden Grove", "state": "California" }, { "city": "National City", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00259870" }, { "nct_id": "NCT04697069", "title": "A Study to Evaluate of the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Acneiform Rash", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acneiform Eruptions" ], "interventions": [ { "name": "Imsidolimab", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Vanda Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 4, "start_date": "2021-05-04", "completion_date": "2021-12-13", "has_results": true, "last_update_posted_date": "2025-09-22", "last_synced_at": "2026-11-01T19:20:19.346Z", "location_count": 5, "location_summary": "Tampa, Florida • Boston, Massachusetts • St Louis, Missouri + 2 more", "locations": [ { "city": "Tampa", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Columbus", "state": "Ohio" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04697069" }, { "nct_id": "NCT04474483", "title": "Safety and Efficacy of Melatonin in Outpatients Infected With COVID-19", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "COVID-19" ], "interventions": [ { "name": "Melatonin", "type": "DRUG" }, { "name": "Placebo (Methylcellulose) capsule", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "State University of New York at Buffalo", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 8, "start_date": "2020-11-06", "completion_date": "2022-07-22", "has_results": true, "last_update_posted_date": "2024-02-07", "last_synced_at": "2026-11-01T19:20:19.346Z", "location_count": 1, "location_summary": "Buffalo, New York", "locations": [ { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04474483" }, { "nct_id": "NCT06841705", "title": "Early Vedolizumab as First-Line for Immune-Related Colitis Therapy Trial", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Immune Checkpoint Inhibitor-Related Colitis" ], "interventions": [ { "name": "Vedolizumab 300 MG Injection [Entyvio]", "type": "DRUG" }, { "name": "Prednisone (and methylprednisolone)", "type": "DRUG" }, { "name": "Prednisone Taper", "type": "DRUG" }, { "name": "Placebo Prednisone Capsules", "type": "OTHER" }, { "name": "Placebo Vedolizumab", "type": "OTHER" }, { "name": "Sulfamethoxazole-Trimethoprim", "type": "OTHER" }, { "name": "Placebo for Sulfamethoxazole-Trimethoprim", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Shilpa Grover, MD, MPH", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 80, "start_date": "2025-07-15", "completion_date": "2026-12-31", "has_results": false, "last_update_posted_date": "2025-11-04", "last_synced_at": "2026-11-01T19:20:19.346Z", "location_count": 2, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT06841705" }, { "nct_id": "NCT02198794", "title": "Reducing Involuntary Movements in Participants With Tardive Dyskinesia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Tardive Dyskinesia" ], "interventions": [ { "name": "SD-809", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Auspex Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 343, "start_date": "2014-10-20", "completion_date": "2020-12-14", "has_results": true, "last_update_posted_date": "2022-04-01", "last_synced_at": "2026-11-01T19:20:19.346Z", "location_count": 44, "location_summary": "Tuscaloosa, Alabama • Anaheim, California • Glendale, California + 36 more", "locations": [ { "city": "Tuscaloosa", "state": "Alabama" }, { "city": "Anaheim", "state": "California" }, { "city": "Anaheim", "state": "California" }, { "city": "Glendale", "state": "California" }, { "city": "Irvine", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02198794" }, { "nct_id": "NCT01283594", "title": "Safety and Efficacy Study of SYN115 in Parkinson's Patients Using Levodopa to Treat End of Dose Wearing Off", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Parkinson's Disease" ], "interventions": [ { "name": "Tozadenant (SYN115) 60 mg BID", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Levodopa (L-dopa)", "type": "DRUG" }, { "name": "Tozadenant (SYN115) 120 mg BID", "type": "DRUG" }, { "name": "Tozadenant (SYN115) 180 mg BID", "type": "DRUG" }, { "name": "Tozadenant (SYN115) 240 mg BID", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Biotie Therapies Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "30 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "30 Years to 80 Years" }, "enrollment_count": 420, "start_date": "2011-03", "completion_date": "2012-10", "has_results": false, "last_update_posted_date": "2019-01-17", "last_synced_at": "2026-11-01T19:20:19.346Z", "location_count": 40, "location_summary": "Birmingham, Alabama • La Jolla, California • Loma Linda, California + 37 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "La Jolla", "state": "California" }, { "city": "Loma Linda", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Oxnard", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01283594" }, { "nct_id": "NCT00634556", "title": "Dopaminergic Effects on Cortical Function in Tourette's (Levodopa Protocol)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Tourette Syndrome" ], "interventions": [ { "name": "levodopa solution 2mg/ml for i.v. use", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 49, "start_date": "2006-02", "completion_date": "2010-10", "has_results": false, "last_update_posted_date": "2018-02-12", "last_synced_at": "2026-11-01T19:20:19.346Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT00634556" }, { "nct_id": "NCT01764256", "title": "A Phase 1 Dose Escalation Study to Examine the Safety of the P2-VP8 Rotavirus Vaccine", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Rotavirus Infection" ], "interventions": [ { "name": "P2-VP8 subunit rotavirus vaccine", "type": "BIOLOGICAL" }, { "name": "placebo", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "PATH", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "ALL", "summary": "18 Years to 45 Years" }, "enrollment_count": 48, "start_date": "2012-12", "completion_date": "2013-09", "has_results": true, "last_update_posted_date": "2019-03-12", "last_synced_at": "2026-11-01T19:20:19.346Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01764256" }, { "nct_id": "NCT02181231", "title": "Buprenorphine Used With Treatment Resistant Depression in Older Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Major Depressive Disorder", "Depression" ], "interventions": [ { "name": "venlafaxine XR", "type": "DRUG" }, { "name": "buprenorphine", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 18, "start_date": "2016-06-01", "completion_date": "2018-04-30", "has_results": true, "last_update_posted_date": "2019-06-04", "last_synced_at": "2026-11-01T19:20:19.346Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT02181231" } ] }